Conexeu: Regenerative Aesthetics & Tissue Reconstruction

Conexeu is advancing a patented, clinically validated collagen scaffold platform designed to disrupt the aesthetics and wound care markets with a single scalable product. Delivered as a liquid skin substitute that gels in approximately 10 minutes, the technology addresses major shortcomings of existing solutions, including safety risks, invasiveness, and inconsistent clinical outcomes. The platform is protected by a strong global IP portfolio with patents granted across the U.S., Europe, Japan, Australia, and Canada, supported by over $4.5 million and more than a decade of R&D, with clinical validation demonstrated in pilot studies. Targeting two large and growing markets, $8.25B in aesthetics and $22.5B in wound care, Conexeu benefits from an accelerated regulatory pathway, multiple indications, and a capital-efficient route to commercialization with diversified revenue potential.